Outset Medical, Inc. (NASDAQ:OM) Q3 2023 Earnings Call Transcript November 7, 2023 5:00 PM ET
Company Participants
Jim Mazzola - VP, IR
Leslie Trigg - Chair & CEO
Nabeel Ahmed - CFO
Conference Call Participants
Rick Wise - Stifel
Josh Jennings - T.D. Cowen
Kristen Stewart - CL King
Suraj Kalia - Oppenheimer & Company
Operator
Good day, and thank you for standing by. Welcome to the Outset Medical Q3 2023 Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Jim Mazzola, Head of Investor Relations. Please go ahead.
Jim Mazzola
Okay. Thank you. Good afternoon, everyone, and welcome to our Third Quarter 2023 earnings call. Here with me today are Leslie Trigg, Chair and Chief Executive Officer; and Nabeel Ahmed, Chief Financial Officer. We issued a news release after the close of market today and updated our investor presentation, both of which can be found on the Investor Relations page at outsetmedical.com.
This call is being recorded and will be archived on the Investors section of our website. It is our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. These statements relate to expectations or predictions of future events, are based on our current estimates and various assumptions, and involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied.
Outset assumes no obligation to update these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of out public filings with the Securities and Expansion, including our latest annual and quarterly reports.
With that, I will now turn the call over to Leslie.
Leslie Trigg
Thanks, Jim. Good afternoon, everyone, and thank you for joining us. A few weeks ago, we provided our preliminary Third Quarter results and share detailed headwinds that will continue to affect our business through this year and into next. Today, we will review our results for the full quarter, share an update on the actions we have taken to adapt and respond to the current environment, and provide our outlook for 2024 and the longer term.
We will also discuss what has not changed. Despite some recent setbacks, all the structural tailwinds remain in place. We are on the front end of growth into two very large end markets anchored by 36 million patients living with chronic kidney disease.